Neurocrine Biosciences has entered into agreements with multiple companies to resolve patent litigation related to their medication INGREZZA, allowing these companies to sell generic versions of the medication in the United States starting in 2038.
AI Assistant
NEUROCRINE BIOSCIENCES INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.